Lupin gets USFDA nod for billion-dollar biosimilar injection used to treat cancer

As per the IQVIA MAT data, pegfilgrastim 6 mg / 0.6 mL injection for subcutaneous use in a single-dose prefilled syringe had estimated annual sales of $1,295 million in the US for the 12 months ending September 2025.

Leave a Reply

Your email address will not be published. Required fields are marked *